High throughput analysis of 10 microsatellite and 11 diallelic polymorphisms on the human Y-chromosome von Thomas, M.G., Bradman, N., Flinn, H.M.

Volltext

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial von Hochhaus, A, Saglio, G, Hughes, T P, Larson, R A, Kim, D-W, Issaragrisil, S, le Coutre, P D, Etienne, G, Dorlhiac-Llacer, P E, Clark, R E, Flinn, I W, Nakamae, H, Donohue, B, Deng, W, Dalal, D, Menssen, H D, Kantarjian, H M

Volltext

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up von Larson, R A, Hochhaus, A, Hughes, T P, Clark, R E, Etienne, G, Kim, D-W, Flinn, I W, Kurokawa, M, Moiraghi, B, Yu, R, Blakesley, R E, Gallagher, N J, Saglio, G, Kantarjian, H M

Volltext

Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results von Advani, Ranjana H., Flinn, Ian, Popplewell, Leslie, Forero-Torres, Andres, Bartlett, Nancy L., Ghosh, Nilanjan, Kline, Justin Paul, Tran, Thu, Lynn, Judith, Chen, James Y, Agoram, Balaji, Huang, Jenny, Takimoto, Chris H.M., Chao, Mark, Smith, Sonali M.

Volltext

ZANUBRUTINIB PLUS OBINUTUZUMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) von Tam, C.S., Quach, H., Nicol, A., Badoux, X., Rose, H., Prince, H.M., Leahy, M.F., Eek, R., Wickham, N., Patil, S.S., Huang, J., Prathikanti, R., Wang, L., Reed, W., Flinn, I.W.

Volltext

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up von Larson, R.A, Hochhaus, A, Hughes, T.P, Clark, R.E, Etienne, G, Kim, D.-W, Flinn, I.W, Kurokawa, M, Moiraghi, B, Yu, R, Blakesley, R.E, Gallagher, N.J, Saglio, G, Kantarjian, H.M

Volltext

ZANUBRUTINIB PLUS OBINUTUZUMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) von Tam, C.S., Quach, H., Nicol, A., Badoux, X., Rose, H., Prince, H.M., Leahy, M.F., Eek, R., Wickham, N., Patil, S.S., Huang, J., Prathikanti, R., Wang, L., Reed, W., Flinn, I.W.

Volltext

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial von Hochhaus, A, Saglio, G, Hughes, T.P, Larson, R.A, Kim, D.-W, Issaragrisil, S, le Coutre, P.D, Etienne, G, Dorlhiac-Llacer, P.E, Clark, R.E, Flinn, I.W, Nakamae, H, Donohue, B, Deng, W, Dalal, D, Menssen, H.D, Kantarjian, H.M

Volltext

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up von Larson, R.A, Hochhaus, A, Hughes, T.P, Clark, R.E, Etienne, G, Kim, D.-W, Flinn, I.W, Kurokawa, M, Moiraghi, B, Yu, R, Blakesley, R.E, Gallagher, N.J, Saglio, G, Kantarjian, H.M

Volltext